Revenue Recognition - Narrative (Details) - USD ($)		3 Months Ended		87 Months Ended
	May 05, 2020	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Prior period performance obligation revenue recognized		$ 2,000,000	$ 28,000,000
Overpayment reimbursement liability		2,100,000		$ 2,100,000	$ 5,000,000
Revenue recognized		4,000
Total revenues		329,219,000	545,165,000
Rayaldee
Disaggregation of Revenue [Line Items]
Revenue recognized		5,100,000	5,800,000
Total revenues		13,479,000	15,645,000
Transfer of intellectual property and other
Disaggregation of Revenue [Line Items]
Total revenues		5,962,000	4,269,000
Products | Transfer of intellectual property and other
Disaggregation of Revenue [Line Items]
Total revenues	$ 3,000,000
Pfizer | Products
Disaggregation of Revenue [Line Items]
Revenue recognized				$ 0
Pfizer | Products | Transfer of intellectual property and other
Disaggregation of Revenue [Line Items]
Total revenues		2,200,000	$ 2,800,000
VFMCRP | Products | Transfer of intellectual property and other
Disaggregation of Revenue [Line Items]
Total revenues		$ 3,000,000